missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human PDE1C (aa 425-512) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (94%), Rat (94%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-54497 (PA5-54497. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Cyclic nucleotide phosphodiesterases (PDEs) catalyze hydrolysis of the cyclic nucleotides cAMP and cGMP to the corresponding nucleoside 5-prime-monophosphates. Mammalian PDEs have been classified into several families based on their biochemical properties. Members of the PDE1 family, such as PDE1C, are calmodulin -dependent PDEs (CaM-PDEs) that are stimulated by a calcium-calmodulin complex (Repaske et al., 1992 ).
Specifications
Specifications
| Accession Number | Q14123 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 5137 |
| Name | Human PDE1C (aa 425-512) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 3',5'-cyclic-AMP phosphodiesterase; 3',5'-cyclic-GMP phosphodiesterase; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 C; cam-PDE 1 C; cyclic nucleotide phosphodiesterase 1 C; Hcam3; hCam-3; Human 3',5' cyclic nucleotide phosphodiesterase (HSPDE1C1A); PDE1C; phosphodiesterase 1 C; phosphodiesterase 1 C calmodulin-dependent (70 kD); phosphodiesterase 1 C, calmodulin-dependent 70 kDa |
| Common Name | PDE1C |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction